{"success":true,"data":{"pressRelease":{"id":"139453","rtpr_id":"nGNXcgzs7J-20260909","ticker":"ZEAL","exchange":"NASDAQ","all_tickers":["ZEAL","ZELA"],"title":"Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference","author":"Globe Newswire","published_at":"2026-09-09T15:00:00.298Z","article_body":"Press release – No. 15 / 2026\n\nZealand Pharma to participate in the Morgan Stanley 24(th) Annual Global\nHealthcare Conference\n\nCopenhagen, Denmark, September 9, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL)\n(CVR-no. 20045078), a biotechnology company transforming the future of\nmetabolic health, announced that Chief Executive Officer, Adam Steensberg,\nwill participate in a fireside chat at the Morgan Stanley 24(th) Annual Global\nHealthcare Conference in New York on Wednesday, September 16, 2026, at 11:30am\nEDT (5:30pm CEST).\n\nA live audio webcast of the fireside chat will be available at\nhttps://event.webcasts.com/starthere.jsp?ei=1773811&tp_key=f2cb5f5403&tp_special=8,\nand accessible through the company’s website at\nhttps://www.zealandpharma.com/investors/events-presentations/, where a\nrecording of the webcast will also be archived after the event.\n\nAbout Zealand Pharma\nZealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on\nadvancing medicines for obesity and metabolic health. Combining more than 25\nyears of peptide R&D expertise with a proprietary data platform that leverages\nadvanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new\nera in obesity and metabolic health. To date, more than 10 Zealand Pharma\ninvented drug candidates have entered clinical development, of which two\nproducts have reached the market and three candidates are in late-stage\ndevelopment. The Company has collaborations with global pharmaceutical and\nbiotechnology partners for research, development, and commercialization.\nFounded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with\na U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.\n\nContacts\nEric Rojas (Investors)\nVice President, Head of Investor Relations\nZealand Pharma\nEmail: erojas@zealandpharma.com\n\nNeshat Anis Ahmadi (Investors)\nInvestor Relations Manager\nZealand Pharma\nEmail: neahmadi@zealandpharma.com\n\nRachel James-Owens (Media)\nVice President, Corporate Communications & Media Relations\nZealand Pharma\nEmail: RJamesOwens@zealandpharma.com\n\nAndreas Hylleberg Mølleskov (Media)\nDirector, External Communications\nZealand Pharma\nEmail: ahylleberg@zealandpharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/31b5d115-c4a3-4dfd-b20e-d222199c4862)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNXcgzs7J-20260909","title":"Zealand Pharma to participate in the Morgan Stanley 24th Annual Global Healthcare Conference","author":"Globe Newswire","ticker":"ZEAL","created":"2026-09-09T15:00:00.298Z","tickers":["ZEAL","ZELA"],"exchange":"NASDAQ","article_body":"Press release – No. 15 / 2026\n\nZealand Pharma to participate in the Morgan Stanley 24(th) Annual Global\nHealthcare Conference\n\nCopenhagen, Denmark, September 9, 2026 - Zealand Pharma A/S (Nasdaq: ZEAL)\n(CVR-no. 20045078), a biotechnology company transforming the future of\nmetabolic health, announced that Chief Executive Officer, Adam Steensberg,\nwill participate in a fireside chat at the Morgan Stanley 24(th) Annual Global\nHealthcare Conference in New York on Wednesday, September 16, 2026, at 11:30am\nEDT (5:30pm CEST).\n\nA live audio webcast of the fireside chat will be available at\nhttps://event.webcasts.com/starthere.jsp?ei=1773811&tp_key=f2cb5f5403&tp_special=8,\nand accessible through the company’s website at\nhttps://www.zealandpharma.com/investors/events-presentations/, where a\nrecording of the webcast will also be archived after the event.\n\nAbout Zealand Pharma\nZealand Pharma A/S (Nasdaq: ZEAL) is a biotechnology company focused on\nadvancing medicines for obesity and metabolic health. Combining more than 25\nyears of peptide R&D expertise with a proprietary data platform that leverages\nadvanced data driven and AI/ML approaches, Zealand Pharma aims to lead a new\nera in obesity and metabolic health. To date, more than 10 Zealand Pharma\ninvented drug candidates have entered clinical development, of which two\nproducts have reached the market and three candidates are in late-stage\ndevelopment. The Company has collaborations with global pharmaceutical and\nbiotechnology partners for research, development, and commercialization.\nFounded in 1998, Zealand Pharma is headquartered in Copenhagen, Denmark, with\na U.S. presence in Boston, Massachusetts. Learn more at www.zealandpharma.com.\n\nContacts\nEric Rojas (Investors)\nVice President, Head of Investor Relations\nZealand Pharma\nEmail: erojas@zealandpharma.com\n\nNeshat Anis Ahmadi (Investors)\nInvestor Relations Manager\nZealand Pharma\nEmail: neahmadi@zealandpharma.com\n\nRachel James-Owens (Media)\nVice President, Corporate Communications & Media Relations\nZealand Pharma\nEmail: RJamesOwens@zealandpharma.com\n\nAndreas Hylleberg Mølleskov (Media)\nDirector, External Communications\nZealand Pharma\nEmail: ahylleberg@zealandpharma.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/31b5d115-c4a3-4dfd-b20e-d222199c4862)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-09T15:00:00.332765273Z","server_sent_at_ms":1788966000332},"received_at":"2026-09-09T15:00:00.386Z","source_url":null},"analysis":{"id":"128288","press_release_id":"139453","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":[],"eventType":"other","narrative":"Zealand Pharma CEO Adam Steensberg will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Wednesday, September 16, 2026, at 11:30am EDT (5:30pm CEST).\n\nA live audio webcast will be available via the company's investor relations website, with an archived recording posted after the event.\n\nThis is a routine IR calendar item with no new financial, clinical, or regulatory disclosure; any signal would come from commentary made during the fireside chat itself.","sentiment":"neutral","agentHooks":{"shouldPost":false,"suggestedAngle":"Routine conference appearance -- low signal on its own, but the fireside chat could surface obesity-pipeline commentary worth monitoring."},"keyFigures":{},"namedEntities":{"people":[{"name":"Adam Steensberg","role":"Chief Executive Officer"},{"name":"Eric Rojas","role":"Vice President, Head of Investor Relations"},{"name":"Rachel James-Owens","role":"Vice President, Corporate Communications & Media Relations"}],"products":[],"companies":[{"name":"Zealand Pharma A/S","ticker":"ZEAL","relationship":"filer"},{"name":"Morgan Stanley","relationship":"conference host"}],"dollarAmounts":[]},"materialImpact":{"score":1,"reasoning":"Routine investor-relations calendar announcement: CEO participation in a fireside chat at a healthcare conference. Contains no financial, clinical, regulatory, or corporate-action disclosure."},"tickerRelevance":{"others":[],"primary":"ZEAL"},"globalImportance":8,"audienceRelevance":15,"eventTypeSecondary":[],"importanceComponents":{"tickerTier":"mid-cap biotech","eventGravity":"conference-participation-boilerplate","sectorWeight":"obesity space carries elevated retail interest","issuerAuthored":true,"newInformationContent":"none"}},"event_type":"other","event_type_secondary":null,"sentiment":"neutral","material_impact_score":1,"narrative":"Zealand Pharma CEO Adam Steensberg will participate in a fireside chat at the Morgan Stanley 24th Annual Global Healthcare Conference in New York on Wednesday, September 16, 2026, at 11:30am EDT (5:30pm CEST).\n\nA live audio webcast will be available via the company's investor relations website, with an archived recording posted after the event.\n\nThis is a routine IR calendar item with no new financial, clinical, or regulatory disclosure; any signal would come from commentary made during the fireside chat itself.","key_figures":{},"named_entities":{"people":[{"name":"Adam Steensberg","role":"Chief Executive Officer"},{"name":"Eric Rojas","role":"Vice President, Head of Investor Relations"},{"name":"Rachel James-Owens","role":"Vice President, Corporate Communications & Media Relations"}],"products":[],"companies":[{"name":"Zealand Pharma A/S","ticker":"ZEAL","relationship":"filer"},{"name":"Morgan Stanley","relationship":"conference host"}],"dollarAmounts":[]},"model_name":"glm-5.3-flash","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-09T15:00:18.884Z","global_importance":8,"audience_relevance":15,"importance_components":{"tickerTier":"mid-cap biotech","eventGravity":"conference-participation-boilerplate","sectorWeight":"obesity space carries elevated retail interest","issuerAuthored":true,"newInformationContent":"none"}},"durationMs":18489,"modelName":"glm-5.3-flash"}}